Ensitrelvir for Covid-19 postexposure prophylaxis in household contacts (Registro nro. 22902)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03207nam a2200301 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260902160450.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Hayden, Frederick G. |
| 9 (RLIN) | 54466 |
| 245 ## - Titulo | |
| Titulo | Ensitrelvir for Covid-19 postexposure prophylaxis in household contacts |
| 300 ## - Páginas | |
| Paginación | páginas: 1905-1915 |
| 520 ## - Resumen | |
| Resumen | Background: Ensitrelvir, an oral inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3C-like protease, is approved in Japan for the treatment of mild-to-moderate coronavirus disease 2019 (Covid-19). Previously, no antiviral agents were approved for postexposure prophylaxis in household contacts of patients with Covid-19. Methods: In this double-blind, randomized, placebo-controlled trial, we randomly assigned persons who were SARS-CoV-2–negative on local diagnostic testing but were household contacts of a patient with Covid-19 (the index patient) to receive either ensitrelvir (375 mg on day 1 and 125 mg daily on days 2 through 5) or placebo within 72 hours after symptom onset in the index patient. The primary end point was Covid-19 (defined by a central laboratory–confirmed positive reverse-transcriptase–polymerase-chain-reaction assay and the presence of ≥1 of 14 prespecified Covid-19 symptoms lasting ≥48 hours) by day 10 in a household contact in the modified intention-to-treat population (all the participants who underwent randomization, had a central laboratory–confirmed negative RT-PCR test for SARS-CoV-2 at baseline, and received at least one dose of the trial drug or placebo). Results: The modified intention-to-treat population included 1030 participants in the ensitrelvir group and 1011 in the placebo group. The mean age of the participants was 42.4 years; 71.1% had undergone randomization within 48 hours after symptom onset in the index patient, and 37.0% had at least one risk factor for severe Covid-19. The incidence of Covid-19 was lower in the ensitrelvir group than in the placebo group (2.9% vs. 9.0%; risk ratio, 0.33; 95% confidence interval [CI], 0.22 to 0.49; P<0.001). The incidence of adverse events during the trial was similar in the two groups (15.1% in the ensitrelvir group and 15.5% in the placebo group), as was the incidence of serious adverse events (0.2% in each group). No Covid-19–related hospitalizations or deaths were reported. Conclusions: Ensitrelvir administered to household contacts of a patient with Covid-19 within 72 hours after symptom onset in the index patient was effective in preventing Covid-19 in the contacts. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CORONAVIRUS |
| 9 (RLIN) | 39659 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | SALUD GLOBAL |
| 9 (RLIN) | 10472 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ENFERMEDADES INFECCIOSAS GENERALES |
| 9 (RLIN) | 54087 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | INFECCIONES VIRALES |
| 9 (RLIN) | 53766 |
| 700 ## - Autor Personal | |
| Autor Personal | Shinkai, Masaharu |
| 9 (RLIN) | 54467 |
| 700 ## - Autor Personal | |
| Autor Personal | Clark, Tristan W. |
| 9 (RLIN) | 54468 |
| 700 ## - Autor Personal | |
| Autor Personal | Luetkemeyer, Anne F. |
| 9 (RLIN) | 54469 |
| 700 ## - Autor Personal | |
| Autor Personal | Sax, Paul E. |
| 9 (RLIN) | 54470 |
| 700 ## - Autor Personal | |
| Autor Personal | Hanage, William P. |
| 9 (RLIN) | 54471 |
| 700 ## - Autor Personal | |
| Autor Personal | Gebo, Kelly A. |
| 9 (RLIN) | 54472 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22669 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM014 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-08-31 |
| Catalogador | sqb |
No hay ítems disponibles.